Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRP-9003 in Limb Girdle Muscular Dystrophy 2E/R4
NCT06246513Phase 3Active, not recruiting
- Sponsor
- Sarepta Therapeutics
- Start
- Jan 2024
- Primary completion
- Mar 2025
- Countries
- 6
01
Overview
A Phase 3 trial of bidridistrogene xeboparvovec in Limb-Girdle Muscular Dystrophy Type 2E (LGMD2E), sponsored by Sarepta Therapeutics. Started Jan 2024; status: active, not recruiting.
02
Drugs
bidridistrogene xeboparvovec
03
Conditions
Limb-Girdle Muscular Dystrophy Type 2E (LGMD2E)
Beyond the preview
Go deeper on NCT06246513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06246513.